2 Information about fostamatinib

Marketing authorisation indication

2.1 Fostamatinib (Tavlesse, Grifols) is indicated 'for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics.

Price

2.3 The list prices of fostamatinib are:

  • £3,090 per 60‑tablet pack; each tablet contains 100 mg of fostamatinib (excluding VAT; BNF online, accessed October 2020)

  • £4,635 per 60‑tablet pack; each tablet contains 150 mg of fostamatinib (excluding VAT; BNF online, accessed October 2020).

    The company has a commercial arrangement, which would have applied if the technology had been recommended.

  • National Institute for Health and Care Excellence (NICE)